We observed that the majority of NPC patients harbored loss of CDKN2A/2B and/or CCND1 amplification, suggesting this subset of NPC patients could benefit from CDK4/6 inhibitors. This evidence concerns the gene CDKN2A and nasopharyngeal carcinoma.